IFIH1 and myositis disease: According to the myositis-specific autoantibodies associated with ILD, the one-year survival rate was 66% for anti-MDA5 antibody-positive patients, 96% for anti-ARS antibody-positive patients, and 95% for both antibody-negative cases [48].